Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets.
Shimada M, Taniguchi H, Yamaguchi H, Gyotoku H, Sasaki D, Kaku N, Senju C, Senju H, Imamura E, Takemoto S, Yamamoto K, Sakamoto N, Obase Y, Tsuchiya T, Fukuda M, Soda H, Ashizawa K, Fukuoka J, Nagayasu T, Yanagihara K, Mukae H. Shimada M, et al. Among authors: senju h. Transl Lung Cancer Res. 2023 Apr 28;12(4):707-718. doi: 10.21037/tlcr-22-794. Epub 2023 Mar 23. Transl Lung Cancer Res. 2023. PMID: 37197618 Free PMC article.
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S; Nagasaki Thoracic Oncology Group. Ikeda T, et al. Among authors: senju h. Cancer Chemother Pharmacol. 2014 Sep;74(3):497-502. doi: 10.1007/s00280-014-2527-4. Epub 2014 Jul 18. Cancer Chemother Pharmacol. 2014. PMID: 25034978 Free article. Clinical Trial.
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: senju h. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
A case series of histoplasmosis patients with elevated serum soluble interleukin-2 receptor levels.
Hirayama T, Takazono T, Iwata K, Senju H, Shimazaki T, Tashiro M, Saijo T, Tanaka T, Nakamura S, Imamura Y, Kojiro M, Miyazaki T, Tsukamoto M, Furumoto A, Morimoto K, Muraosa Y, Matsubara Y, Yanagihara K, Mukae H, Kamei K, Kohno S, Izumikawa K. Hirayama T, et al. Among authors: senju h. J Infect Chemother. 2017 Sep;23(9):642-647. doi: 10.1016/j.jiac.2017.03.006. Epub 2017 Apr 8. J Infect Chemother. 2017. PMID: 28395939
Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.
Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H, Shimada M, Ikeda T, Yamaguchi H, Nakatomi K, Hayashi N, Soda H, Mukae H. Takemoto S, et al. Among authors: senju h. Thorac Cancer. 2017 Nov;8(6):577-581. doi: 10.1111/1759-7714.12483. Epub 2017 Aug 3. Thorac Cancer. 2017. PMID: 28771961 Free PMC article. Clinical Trial.
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
Takemoto S, Nakamura Y, Gyoutoku H, Senju H, Ogawara D, Ikeda T, Yamaguchi H, Kitazaki T, Nakano H, Nakatomi K, Tomari S, Sato S, Nagashima S, Fukuda M, Mukae H. Takemoto S, et al. Among authors: senju h. Thorac Cancer. 2019 Mar;10(3):452-458. doi: 10.1111/1759-7714.12958. Epub 2019 Jan 9. Thorac Cancer. 2019. PMID: 30628188 Free PMC article. Clinical Trial.
36 results